What Libbs Farmacêutica does

Libbs Farmacêutica is a privately held, family-controlled Brazilian pharmaceutical company founded in 1958 and headquartered in São Paulo. It develops, manufactures and commercializes more than 100 pharmaceutical brands across 240 presentations, spanning eight therapeutic areas: cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, central nervous system and respiratory. The company's products reach 94,000+ pharmacies and drugstores across Brazil, with a field sales force visiting 86,000+ physicians in 1,175 cities; 13.5+ million patients were treated with Libbs products in 2025. The firm also operates the Biotec biotechnology platform in Embu das Artes, the first industrial-scale single-use bioreactor facility in Brazil, which produces domestic biosimilar monoclonal antibodies including rituximab, bevacizumab and trastuzumab.

The company's core technology base combines small-molecule pharmaceutical manufacturing at its 151,000 m² industrial complex in Embu das Artes with the Biotec biosimilar facility developed via technology partnership with Mabxience (Chemo) and supplemented by co-development arrangements with Biocon, Mylan and Polpharma Biologics. The Biotec Multipurpose Line extends the platform into mRNA development, CDMO services for external partners, and partnerships with universities and research institutes. In 2024 the company inaugurated the Planta Piloto Biotec for bioprocess scale-up and clinical material production, plus Brazil's first High-Potency Drug Factory for advanced oncology. Vertically integrated API production is anchored by subsidiary Libbs Farmoquímica Ltda (since 2006).

Libbs generates revenue primarily through one-time sales of pharmaceutical and biosimilar products via retail pharmacy distribution plus an institutional/hospital channel for oncology, augmented by CDMO services and exclusive distribution deals with multinational partners including Pfizer (palbociclib), Eli Lilly (galcanezumab) and Mithra Pharmaceuticals (drospirenone+estetrol oral contraceptive). The company reaches patients through retail pharmacy distribution, healthcare professional engagement, and content platforms A Vida Plena and Trate da Vida. R&D investment reached R$208.49 million in 2025, supporting in-house programs such as the Research Incentive Program (PIP) and open innovation program Linna. Pricing is not publicly disclosed and the company is privately held with no parent or institutional investor disclosed.

Name

Libbs Farmacêutica

Legal name

Libbs Farmacêutica Ltda

Website

https://libbs.com.br

Company type

Private

Founded year

1958

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Libbs Farmacêutica is a privately held Brazilian pharmaceutical company founded in 1958 that develops, manufactures, and commercializes over 100 pharmaceutical brands across eight therapeutic areas, including Brazil's first industrial-scale biosimilar monoclonal antibody facility, serving patients through 94,000+ pharmacies nationwide.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Pharmaceutical manufacturing
• Biosimilar medications
• Monoclonal antibody production
• Contract manufacturing services
• Specialty pharmaceutical products

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Development, manufacturing and commercialization of prescription and OTC pharmaceutical products across multiple therapeutic areas including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, CNS and respiratory.
2. Biosimilar Medications: Production and commercialization of biological and biosimilar medications for complex diseases including cancer and autoimmune diseases. Includes rituximab, bevacizumab, trastuzumab and other monoclonal antibodies.
3. CDMO Services: Contract development and manufacturing services for other pharmaceutical companies using the Biotec multipurpose platform.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Libbs Farmacêutica develops, manufactures, and commercializes a portfolio of 100+ pharmaceutical brands across 240+ presentations in eight therapeutic areas, including cardiometabolic, dermatology, gastroenterology, gynecology, hematology, oncology, respiratory, and central nervous system conditions. The company operates Brazil's first industrial-scale single-use bioreactor platform (Biotec) producing biosimilar monoclonal antibodies such as rituximab, bevacizumab, and trastuzumab, and offers contract development and manufacturing (CDMO) services. Its products reach Brazilian patients through 94,000+ pharmacies and 86,000+ physician visits by a national field sales force.

Product overview

Libbs Farmacêutica is a Brazilian pharmaceutical company with a diversified portfolio of over 100 brands across 240 presentations. The company operates across multiple therapeutic areas including Cardiometabólicos, Dermatológicos, Gástricos, Ginecológicos, Hematológicos, Oncológicos, Respiratórios, and Sistema Nervoso Central. Key products include biosimilar monoclonal antibodies (Trastuzumabe for breast cancer, Rituximabe for lymphoma/leukemia, Bevacizumabe for lung cancer), consumer health products (Maxidrate nasal gel, Muvinlax laxative), and an innovative oral contraceptive combining drospirenone with estetrol. The company operates through multiple platforms including Biotec for biologics manufacturing, open innovation program Linna, and internal AI assistant LIS. Products are supported by patient portal A Vida Plena and healthcare professional portal Trate da Vida.

Differentiator

Problem solved

Functional benefit

Products and services

• Trastuzumabe Biosimilar monoclonal antibody indicated for the treatment of metastatic breast cancer. First Trastuzumab biosimilar commercialized in Brazil, co-developed with Biocon and Mylan and brought exclusively to Brazil by Libbs.
• Rituximabe Monoclonal antibody produced domestically for treatment of non-Hodgkin lymphoma and chronic lymphoid leukemia. First monoclonal antibody produced at industrial scale in Brazil using Libbs' Biotec single-use bioreactor platform.
• Bevacizumabe Monoclonal antibody biosimilar indicated for lung cancer treatment, produced via Libbs' Biotec single-use bioreactor platform.
• Muvinlax Laxative medication for treatment of intestinal constipation symptoms, sold as an over-the-counter consumer health product through Brazilian retail pharmacies.
• Maxidrate Nasal hydration gel for children and adults, preventing nasal dryness. Contains exclusive Ringer Lactate formulation, free of preservatives and vasoconstrictors. Sold through Brazilian retail pharmacies as a consumer health product.
• Contraceptive with drospirenone and estetrol Innovative combined oral contraceptive combining drospirenone with estetrol (E4), a natural-identical estrogen produced from plant sources. Marketed as the most innovative combined oral contraceptive in 15 years, offering greater safety with minimal endocrine, metabolic, and hemostatic impact. Partnered with Mithra Pharmaceuticals.
• Tarfic Topical tacrolimus ointment for dermatological treatment, available in 0.3 mg/g and 1 mg/g presentations. Sold through Brazilian retail pharmacies as a prescription dermatological product.
• Linha Multipropósito Biotec (CDMO Services) Contract development and manufacturing (CDMO) service offering using Libbs' Biotec multipurpose biotech line. Provides bioprocess scale-up, biomolecule development, and clinical material production for other pharmaceutical companies, including capabilities in messenger RNA technology. Establishes partnerships with universities, research institutes, and startups.

Quantifiable outcome

• 13.5+ million people treated with Libbs products
• +3 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Polpharma BiologicscoreStrategic or Co-development Partner · 10 December 2025Licensing agreement for a biosimilar for autoimmune diseases. Polpharma Biologics handles development and manufacturing while Libbs commercializes the product in Brazil. The biosimilar is under development and expected to seek approval within three years.
• PfizercoreChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive distribution, promotion and commercialization agreement for Palbociclibe, oral medication for breast cancer treatment. ANVISA registration granted December 2023.
• Eli LillycoreChannel Partner/ Reseller/ Distributor · 1 January 2023Exclusive distribution and commercialization partnership for Galcanezumabe medication for migraine treatment in Brazil.
• Mithra PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2023Partnership for innovative oral contraceptive combining drospirenone with estetrol (E4). ANVISA approval received for commercialization in Brazil in 2023. Estetrol is a natural-identical estrogen produced during pregnancy extracted from plant sources.
• Biocon and MylancoreStrategic or Co-development Partner · 1 January 2018Co-development partnership for Trastuzumab biosimilar for breast cancer treatment. Products codesigned by Biocon and Mylan, brought exclusively to Brazil by Libbs. First Trastuzumab biosimilar commercialized in Brazil in 2018.
• Bio-Manguinhos (Fiocruz)minorStrategic or Co-development Partner · 1 January 2017Partnership for fill-finish of Yellow Fever vaccine distributed throughout Brazil as part of public health initiative.
• BioconcoreTechnology or Integration · 1 January 2016Technology transfer agreement for production of pharmaceutical ingredients Tacrolimo and Sirolimo, achieving 100% verticalization in Tacrolimo production.
• Mabxience (Chemo)coreStrategic or Co-development Partner · 1 January 2013Partnership for production of biological medications. Established Biotec facility for biosimilar development with rituximab and bevacizumab as first products. Mabxience, the biotechnology arm of Chemo, provided technology transfer for single-use bioreactor platform.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Cristália: Brazilian pharmaceutical manufacturer with strong presence in generics, anesthetics, oncology and hospital channel. Comparable to Libbs in oncology portfolio, API vertical integration and Brazilian institutional sales.
• EMS Pharma: Brazil's largest pharmaceutical company by units sold, operating across branded generics, OTC and prescription pharma. Direct competitor to Libbs in Brazilian pharmacy retail with broader therapeutic coverage and larger manufacturing scale.
• Eurofarma: Brazilian multinational pharmaceutical company with operations across branded generics, prescription and biotech. Comparable to Libbs in therapeutic breadth, Brazilian market presence and growing biosimilar/biotech investments.
• Aché Laboratórios: Brazilian pharmaceutical company with diversified portfolio across prescription, OTC and dermatology. Competes with Libbs in cardiology, CNS, gynecology and dermatology segments in the Brazilian retail channel.
• Hyper a Pharma: Largest Brazilian pharma by revenue (formerly Hypermarcas), with broad OTC, prescription and branded generic portfolio. Directly comparable in retail pharmacy positioning, therapeutic breadth and Brazilian market scale.
• Biolab Farmacêutica: Brazilian pharmaceutical company specializing in prescription drugs, dermatology and women's health. Competes with Libbs in dermatology, gynecology and CNS therapeutic areas within the Brazilian market.

Emerging players

• Bionovis: Brazilian joint venture between Aché, EMS, Eurofarma and Hypera focused on biosimilars. Emerging direct competitor to Libbs's Biotec platform in monoclonal antibody biosimilars in Brazil, backed by the country's largest pharma players.
• Biocon Biologics: India-based biosimilar specialist (and existing Libbs partner for trastuzumab). Competes in the same global biosimilar molecules (rituximab, trastuzumab, bevacizumab) and represents both partner and competitive threat to Libbs.

Broad incumbents

• Celltrion: South Korean biosimilar leader with commercialized monoclonal antibody biosimilars across oncology and autoimmune. As global biosimilar manufacturers expand into Latin America, Celltrion represents the most likely multinational competitor to Libbs's oncology biosimilar franchise.
• Pfizer: Global pharma incumbent and existing Libbs partner (exclusive distribution of palbociclib). Competes with Libbs across oncology, cardiology and women's health while simultaneously serving as both collaborator and competitor in the Brazilian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Libbs Farmacêutica